Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Moxetumomab pasudotox-tdfk in heavily retreated r/r hairy cell leukaemia

Dr Robert Kreitman - National Cancer Institute, Bethesda, USA

Moxetumomab pasudotox-tdfk in heavily retreated r/r hairy cell leukaemia ( Dr Robert Kreitman - National Cancer Institute, Bethesda, USA )

Azacitidine plus nivolumab in older adults with AML or MDS

Prof Annette Hay - Queen's University, Ontario, Canada

Azacitidine plus nivolumab in older adults with AML or MDS ( Prof Annette Hay - Queen's University, Ontario, Canada )

Venetoclax chemo combo active and well-tolerated in children with r/r AML

Dr Seth Karol - St. Jude Children’s Research Hospital, Memphis, USA

Venetoclax chemo combo active and well-tolerated in children with r/r AML ( Dr Seth Karol - St. Jude Children’s Research Hospital, Memphis, USA )

Cancer Survivorship - Special Issue

Prof Deborah Fenlon - Swansea University, Swansea, UK

Cancer Survivorship - Special Issue ( Prof Deborah Fenlon - Swansea University, Swansea, UK )

Laser therapy for vulvo-vaginal atrophy / genito-urinary syndrome of menopause...

Prof Deborah Fenlon - Swansea University, Swansea, UK

Laser therapy for vulvo-vaginal atrophy / genito-urinary syndrome of menopause in breast cancer survivors ( Prof Deborah Fenlon - Swansea University, Swansea, UK )

Precision medicine treatment in older AML: Results of Beat AML master trial

Dr Amy Burd - Leukemia and Lymphoma Society, White Plains, USA

Precision medicine treatment in older AML: Results of Beat AML master trial ( Dr Amy Burd - Leukemia and Lymphoma Society, White Plains, USA )

Older patients with non-Hodgkin lymphoma can be treated successfully with CAR T...

Dr Karl Kilgore - Avalere Health, Bowie, USA

Older patients with non-Hodgkin lymphoma can be treated successfully with CAR T-cell therapy ( Dr Karl Kilgore - Avalere Health, Bowie, USA )

Depth of response to daratumumab, lenalidomide, bortezomib, and dexamethasone...

Prof Peter Voorhees - Levine Cancer Institute, Charlotte, USA

Depth of response to daratumumab, lenalidomide, bortezomib, and dexamethasone improves over time in transplant-eligible newly diagnosed multiple myeloma ( Prof Peter Voorhees - Levine Cancer Institute, Charlotte, USA )

CARTITIUDE-1: BCMA-targeted CAR T-cell therapy shows high response rates in...

Prof Deepu Madduri - Mount Sinai, New York, USA

CARTITIUDE-1: BCMA-targeted CAR T-cell therapy shows high response rates in patients with multiple myeloma ( Prof Deepu Madduri - Mount Sinai, New York, USA )

Blinatumomab vs chemotherapy as post-reinduction therapy in HR/IR first relapse...

Dr Patrick Brown - Johns Hopkins University, Baltimore, USA

Blinatumomab vs chemotherapy as post-reinduction therapy in HR/IR first relapse of B-ALL in children and adolescents ( Dr Patrick Brown - Johns Hopkins University, Baltimore, USA )

Identifying prognostic constellations of driver mutations in acute myeloid...

Dr Charles Mullighan - St. Jude Children's Research Hospital, Memphis, USA

Identifying prognostic constellations of driver mutations in acute myeloid leukaemia and myelodysplastic syndromes ( Dr Charles Mullighan - St. Jude Children's Research Hospital, Memphis, USA )

CANDOR: Triple drug combo delays disease progression in stubborn multiple...

Dr Saad Usmani - Levine Cancer Institute, Charlotte, USA

CANDOR: Triple drug combo delays disease progression in stubborn multiple myeloma ( Dr Saad Usmani - Levine Cancer Institute, Charlotte, USA )

More from ecancer